# EXCIVA GmbH: Research, Heidelberg, Germany > EXCIVA GmbH: EXCIVA GmbH is a clinical-stage biopharmaceutical company based in Heidelberg, Germany, founded in 2016. Based in Heidelberg, Germany. Source: https://millionrounds.com/startup/exciva-gmbh (Millionrounds; every figure on the page links to its filing or article) Germany · [Research startup](https://millionrounds.com/companies) # EXCIVA GmbH EXCIVA GmbH is a clinical-stage biopharmaceutical company based in Heidelberg, Germany, founded in 2016. Follow EXCIVA GmbH and see its new rounds in your feed. [Sign up free](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fexciva-gmbh) Funding reported Last round: Series A Research Heidelberg, Germany Company summary - **Founded:** 2016 10 years old - **Team:** 7 1 to 10 people - **Funding reported:** 59.4M as listed, currency not stated - **Last round:** Series A Oct 2021 How sure we are - ✓ **Listed** We know it exists and what it does - 2 **Funding reported** A company dataset reports a raise - 3 **Observed** A filing or a dated announcement confirms a round No round for EXCIVA GmbH has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology) ## About EXCIVA GmbH EXCIVA GmbH is a clinical-stage biopharmaceutical company based in Heidelberg, Germany, founded in 2016. The company specializes in biotechnology research aimed at developing therapies for Alzheimer's disease and other neuropsychiatric conditions. With a small team of 2-10 employees, EXCIVA focuses on the symptomatic management of dementia-related issues, including agitation, aggression, and depression. The company's lead program, EXV-802 (also known as Deraphan), is currently in a Phase 2/3 clinical trial called SERENADA, targeting agitation in Alzheimer's dementia. This program has received Fast Track designation from the US FDA. EXCIVA emphasizes rigorous clinical trials and collaborations to advance its research and aims to enhance patient independence while reducing caregiver distress. The company recently secured €51 million ($59 million) in a Series B financing round and is part of the EQT portfolio through the LSP Dementia Fund. ## What company datasets say EXCIVA GmbH raised Funding, as reported Reported in all **59.4M** in the source's currency Rounds **2** Last round **Series A** Last round size **56.1M** Last round date **Oct 2021** Investors listed **5** ## Founders and team From EXCIVA GmbH's own website: 2 founders, 12 on the team. **Hans J. Moebius** Co-founder and CMO **Sreenivasarao Vepachedu** Co-founder and Patent Attorney - **François Conquet** CEO - **Francisco Orellana** CFO - **Nadine Knowles** COO - **Duc Tran** Head of CMC - **Fiona Hattey** Head of Clinical Operations - **Karl Burgin** Head of Regulatory Affairs - **Aidan King** Member of the Board - **Christoph Kocher** Member of the Board - **Mark Altmeyer** Chairman of Board - **Philip Scheltens** Member of the Board - **Raphaël Wisniewski** Member of the Board - **Vikram Sudarsan** Member of the Board ## On 4 portfolio pages Investors who name them - [Dolby Family Ventures](https://millionrounds.com/fund/dolby-family-ventures) - [Andera Partners](https://millionrounds.com/fund/andera-partners) - [Modi Ventures](https://millionrounds.com/fund/modi-ventures) - [LifeArc Ventures](https://millionrounds.com/fund/lifearc-ventures) Each firm lists EXCIVA GmbH on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source. ## The company, in detail What they build Known for health care dementia symptoms biotechnology research combination therapy non-dopaminergic treatment dementia symptom cluster neurodegeneration serenada study clinical research agitation in dementia hospital & health care symptomatic management medical health 5-ht2a/2c receptor inverse agonist biotechnology Built with from their website Google Cloud Viewport Meta TrustArc Varnish webpack Hornetsecurity Spam and Malware Protection Google Cloud Hosting Priority Hints React Microsoft Exchange +8 more Sirvoy Wix eCommerce Microsoft 365 Apps & Services WebsiteBuilder Mobile Friendly Lodash Open Graph Google Cloud CDN - **Sector:** Research - **Industry code:** NAICS 33911, 541714, SIC 2834, 2836, 8731 - **Region:** Baden-Wuerttemberg - **Full record:** [Every detail in the company directory](https://millionrounds.com/directory/exciva) ## Research in Germany Startups like it - [**SphingoTec** Hennigsdorf · founded 2002 *Raised*](https://millionrounds.com/company/sphingotec) - [**mbiomics GmbH** Neuried · founded 2020 *Raised*](https://millionrounds.com/company/mbiomics-gmbh) - [**PreOmics** Planegg · founded 2016 *Raised*](https://millionrounds.com/company/preomics) - [**CatalYm GmbH** Planegg · founded 2016](https://millionrounds.com/startup/catalym-gmbh) - [**Cellex Cell Professionals** Cologne · founded 2001](https://millionrounds.com/startup/cellex-cell-professionals) - [**Isarna Therapeutics GmbH** Graefelfing · founded 1998](https://millionrounds.com/startup/isarna-therapeutics-gmbh) - [**NVision Quantum Technologies** Ulm · founded 2015](https://millionrounds.com/startup/nvision-quantum-technologies) - [**Resolve Biosciences** Monheim am Rhein · founded 2020](https://millionrounds.com/startup/resolve-biosciences) ## Is this your company? Add your raise, your deck and your story, and put EXCIVA GmbH in front of investors. Or tell us what we have wrong. [List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)